Biomarkers and Case Reports

Vaccines prevent infectious diseases, but vaccination is not without risk and adverse events are reported although they are more commonly reported for biologicals than for vaccines. Vaccines and biologicals must undergo a rigorous assessment before and after licensure to minimize safety concerns. Potential safety concerns should be identified as early as possible during the development of vaccines and biologicals to minimize investment risk. State-of-the-art tools and methods to identify safety concerns and biomarkers that are predictive of clinical outcomes are indispensable. For vaccines and adjuvant formulations, systems biology approaches, supported by single-cell microfluidics applied to translational studies between preclinical and clinical studies, could improve reactogenicity and safety predictions.

    Related Conference of Biomarkers and Case Reports

    June 09-09, 2021

    Global Summit on Vaccines and Immunology

    Chicago, USA
    June 09-10, 2021

    Global Summit on HIV-AIDS and STDs

    Chicago, USA
    June 09-10, 2021

    Global Summit on Vaccines & Emerging Diseases

    Chicago, USA
    June 14-15, 2021

    Global Summit on Hepatitis Vaccine

    Rome, Italy
    July 29-30, 2021

    33rd Annual Congress on Immunology and Vaccinations

    Vancouver, Canada

    Biomarkers and Case Reports Conference Speakers

    Recommended Sessions

    Related Journals

    Are you interested in